tradingkey.logo

Kalvista Pharmaceuticals Inc <KALV.OQ> expected to post a loss of 87 cents a share - Earnings Preview

ReutersMar 7, 2025 1:21 PM
  • Kalvista Pharmaceuticals Inc KALV.OQ KALV.O is expected to show no change in quarterly revenue when it reports results on March 10 (estimated) for the period ending January 31 2025

  • ​LSEG's mean analyst estimate for Kalvista Pharmaceuticals Inc is for a loss of 87 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Kalvista Pharmaceuticals Inc is $28.00​, above​ its last closing price of $11.98. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Oct. 31 2024

-0.90

-0.91

-0.91

Met

-0.2

Jul. 31 2024

-0.92

-0.91

-0.87

Beat

4.8

Apr. 30 2024

-0.84

-0.73

-1.02

Missed

-39.4​

Jan. 31 2024

-0.77

-0.77

-0.84

Missed

-9.5

​​Oct. 31 2023

-0.77

-0.79

-0.80

Missed

-1.7

Jul. 31 2023

-0.84

-0.86

-0.74

Beat

13.8​

Apr. 30 2023

-0.83

-0.94

-0.77

Beat

17.9

Jan. 31 2023

-0.92

-0.98

-0.75

Beat

23.9

This summary was machine generated March 7 at 13:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI